$SGBX
SAFE & GREEN HOLDINGS CORP. Stock $sgbx

$sgbx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000121390022020226 Filed on April 18, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$8.453M	$38.34M	$7.350M
YoY Change	15.0%	337.91%	2061.76%
Cost Of Revenue	$10.28M	$36.01M	$5.750M
YoY Change	78.71%	451.04%	1882.76%
Gross Profit	-$1.823M	$2.329M	$1.610M
YoY Change	-213.25%	4.9%	3120.0%
Gross Profit Margin	-21.57%	6.07%	21.9%
Selling, General & Admin	$347.5K	$329.2K	$3.070M
YoY Change	-88.68%	21.47%	184.26%
% of Gross Profit		14.14%	190.68%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$145.7K	$398.7K	$90.00K
YoY Change	61.9%	687.18%	125.0%
% of Gross Profit		17.12%	5.59%
Operating Expenses	$347.5K	$8.312M	$3.070M
YoY Change	-88.68%	22.18%	184.26%
Operating Profit	-$2.171M	-$5.983M	-$1.460M
YoY Change	48.68%	30.55%	41.75%
Interest Expense	$15.70K	$55.96K	$20.00K
YoY Change	-21.5%	11.92%	-111.11%
% of Operating Profit
Other Income/Expense, Net	$1.130K	$74.48K	$0.00
YoY Change		-0.26%	-100.0%
Pretax Income	-$2.164M	-$5.908M	-$1.440M
YoY Change	50.26%	31.06%	-65.13%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$3.427M	-$10.83M	-$1.630M
YoY Change	110.22%	130.84%	-60.53%
Net Earnings / Revenue	-40.54%	-28.25%	-22.18%
Basic Earnings Per Share		-$1.16
Diluted Earnings Per Share	-$312.5K	-$1.160M	-$188.9K
COMMON SHARES
Basic Shares Outstanding	11.99M shares	9.339M shares	8.596M shares
Diluted Shares Outstanding		9.339M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.02M	$13.02M	$13.01M
YoY Change	0.11%	0.11%	698.16%
Cash & Equivalents	$13.02M	$13.02M	$13.01M
Short-Term Investments
Other Short-Term Assets	$3.200M	$656.3K	$570.0K
YoY Change	461.4%	15.14%	-96.76%
Inventory	$1.274M	$1.274M	$778.1K
Prepaid Expenses
Receivables	$2.918M	$2.960M	$2.636M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.91M	$17.91M	$18.30M
YoY Change	-2.1%	-2.11%	529.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.840M	$8.050M	$2.683M
YoY Change	154.94%	90.76%	22739.99%
Goodwill	$1.309M		$1.309M
YoY Change	0.0%		7.01%
Intangibles	$2.095M		$2.219M
YoY Change	-5.56%		-3.49%
Long-Term Investments	$3.800M	$3.800M
YoY Change
Other Assets	$112.2K	$112.2K	$150.0K
YoY Change	-25.23%	-25.23%	-21.05%
Total Long-Term Assets	$17.01M	$17.01M	$8.584M
YoY Change	98.16%	98.25%	130.27%
TOTAL ASSETS
Total Short-Term Assets	$17.91M	$17.91M	$18.30M
Total Long-Term Assets	$17.01M	$17.01M	$8.584M
Total Assets	$34.92M	$34.92M	$26.88M
YoY Change	29.92%	29.93%	305.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.785M	$7.569M	$3.012M
YoY Change	25.64%	91.13%	42.76%
Accrued Expenses	$318.0K	$318.0K	$310.0K
YoY Change	2.57%	2.57%
Deferred Revenue	$1.438M		$1.775M
YoY Change	-19.0%		950.41%
Short-Term Debt	$23.73K	$1.972M	$0.00
YoY Change
Long-Term Debt Due	$19.49K	$19.49K	$20.00K
YoY Change	-2.55%	-2.55%
Total Short-Term Liabilities	$11.59M	$11.59M	$7.235M
YoY Change	60.15%	60.25%	218.08%
LONG-TERM LIABILITIES
Long-Term Debt	$761.6K	$761.6K	$30.00K
YoY Change	2438.8%	2438.8%
Other Long-Term Liabilities	$860.5K	$860.5K	$1.180M
YoY Change	-27.08%	-27.08%
Total Long-Term Liabilities	$1.622M	$1.622M	$1.210M
YoY Change	34.06%	34.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.59M	$11.59M	$7.235M
Total Long-Term Liabilities	$1.622M	$1.622M	$1.210M
Total Liabilities	$13.21M	$14.57M	$8.444M
YoY Change	56.42%	68.85%	271.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.11M		-$22.28M
YoY Change	48.63%		26.69%
Common Stock	$119.9K		$85.96K
YoY Change	39.44%		642.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.35M	$20.35M	$18.25M
YoY Change
Total Liabilities & Shareholders Equity	$34.92M	$34.92M	$26.88M
YoY Change	29.92%	29.93%	305.18%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$3.427M	-$10.83M	-$1.630M
YoY Change	110.22%	130.84%	-60.53%
Depreciation, Depletion And Amortization	$145.7K	$398.7K	$90.00K
YoY Change	61.9%	687.18%	125.0%
Cash From Operating Activities	$369.7K	-$662.8K	$1.560M
YoY Change	-76.3%	-77.05%	-587.5%
INVESTING ACTIVITIES
Capital Expenditures	-$648.9K	$4.825M	-$1.520M
YoY Change	-57.31%	207.68%
Acquisitions
YoY Change
Other Investing Activities	-$538.8K	-$3.974M	-$90.00K
YoY Change	498.67%	168.48%
Cash From Investing Activities	-$1.188M	-$9.471M	-$1.610M
YoY Change	-26.23%	210.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.55M	$10.15M	0.000
YoY Change		-41.4%	-100.0%
NET CHANGE
Cash From Operating Activities	369.7K	-$662.8K	1.560M
Cash From Investing Activities	-1.188M	-$9.471M	-1.610M
Cash From Financing Activities	10.55M	$10.15M	0.000
Net Change In Cash	9.734M	$14.03K	-50.00K
YoY Change	-19567.36%	-99.88%	-103.11%
FREE CASH FLOW
Cash From Operating Activities	$369.7K	-$662.8K	$1.560M
Capital Expenditures	-$648.9K	$4.825M	-$1.520M
Free Cash Flow	$1.019M	-$5.488M	$3.080M
YoY Change	-66.93%	23.15%	-1062.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms	Total of 526 of restricted stock units were granted to two of the Company’s non-employee directors, under the Incentive Plan, at the calculated fair value of $58.80 and $55.20 per share, respectively, which represents the average closing price of the Company’s common stock for the ten trading days immediately preceding and including the grant date.
CY2021	us-gaap	Restricted Cash And Cash Equivalent Item Description RestrictedCashAndCashEquivalentItemDescription	The event that the Agreement was earlier terminated, CMC was entitled to receive the entire amount of such restricted stock that had vested as of such earlier termination date, but in no event less than 1,250 shares of such restricted stock. The Agreement also provided for customary indemnification and confidentiality obligations between the parties. The 2,500 shares of restricted stock of the Company's common stock has yet to be issued to CMC.
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2037-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001023994
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity File Number EntityFileNumber	001-38037
CY2021	dei	Entity Registrant Name EntityRegistrantName	SG BLOCKS, INC.
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4463937
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	5011 Gate Parkway,
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building 100, Suite 100
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Jacksonville
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32256
CY2021	dei	City Area Code CityAreaCode	(646)
CY2021	dei	Local Phone Number LocalPhoneNumber	240-4235
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021	dei	Trading Symbol TradingSymbol	SGBX
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q2	dei	Entity Public Float EntityPublicFloat	48471319	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12006873	shares
CY2021	dei	Auditor Firm AuditorFirmId	726
CY2021	dei	Auditor Name AuditorName	Whitley Penn LLP
CY2021	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13024381	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13010356	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2635608	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	41916	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1303136	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1273825	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	778144	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	656279	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	570775	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	18298019	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6839943	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2683014	USD
CY2021Q4	sgbx	Project Development Costs And Other Non Current Assets ProjectDevelopmentCostsAndOtherNonCurrentAssets	923172	USD
CY2020Q4	sgbx	Project Development Costs And Other Non Current Assets ProjectDevelopmentCostsAndOtherNonCurrentAssets		USD
CY2021Q4	us-gaap	Goodwill Goodwill	1309330	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1309330	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1210053	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1537545	USD
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	720137	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	682637	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2095232	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2218609	USD
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	112159	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	152944	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	200000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3599945	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures		USD
CY2021Q4	us-gaap	Assets Assets	34924018	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7568851	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3961961	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1437579	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1774740	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	337469	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	326654	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	264451	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	965561	USD
CY2021Q4	us-gaap	Liabilities Of Business Transferred Under Contractual Arrangement Current LiabilitiesOfBusinessTransferredUnderContractualArrangementCurrent	5795	USD
CY2020Q4	us-gaap	Liabilities Of Business Transferred Under Contractual Arrangement Current LiabilitiesOfBusinessTransferredUnderContractualArrangementCurrent	200765	USD
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1971960	USD
CY2020Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable		USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11586105	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7234681	USD
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	750000	USD
CY2020Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm		USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	872124	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1209594	USD
CY2021Q4	us-gaap	Liabilities Liabilities	13208229	USD
CY2020Q4	us-gaap	Liabilities Liabilities	8444275	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5405010	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5405010	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11986873	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11986873	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8596189	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8596189	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	119869	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	85962	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53341405	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40443840	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33109220	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22276546	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20352054	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	18253256	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	1363735	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	61675	USD
CY2021	us-gaap	Revenues Revenues	38341702	USD
CY2020	us-gaap	Revenues Revenues	8755623	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	36012654	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	6535444	USD
CY2021	us-gaap	Gross Profit GrossProfit	2329048	USD
CY2020	us-gaap	Gross Profit GrossProfit	2220179	USD
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4186642	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	184567	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21715789	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18437823	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34924018	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26882098	USD
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	3788024	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	288438	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	230248	USD
CY2020	us-gaap	Other General Expense OtherGeneralExpense	130707	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	8311898	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	6803011	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5982850	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-4582832	USD
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	1254	USD
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	9275	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	57266	USD
CY2021	us-gaap	Other General Expense OtherGeneralExpense	48794	USD
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	62602	USD
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	23282	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44081	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1012	USD
CY2021	sgbx	Gain Loss From Equity Affiliaties GainLossFromEquityAffiliaties	-55	USD
CY2020	sgbx	Gain Loss From Equity Affiliaties GainLossFromEquityAffiliaties		USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	74478	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5908372	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4508162	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2021	us-gaap	Profit Loss ProfitLoss	-5908372	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-4508162	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4924302	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	184567	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10832674	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-4692729	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.16
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9339199	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5959403	shares
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4360149	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1261215	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		USD
CY2020	sgbx	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits	-122	USD
CY2020	sgbx	Conversion Of Debt Exchange Value ConversionOfDebtExchangeValue	206263	USD
CY2020	sgbx	Stock Issued During Period Issuance Of Common Stock Net Of Issuance Costs StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCosts	17118480	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18437823	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1736531	USD
CY2021	sgbx	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits	707188	USD
CY2021	sgbx	Conversion Of Debt Exchange Value ConversionOfDebtExchangeValue	10487753	USD
CY2021	sgbx	Noncontrollinginterestdistribution Noncontrollinginterestdistribution	-3745134	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-5908372	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21715789	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-5908372	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-4508162	USD
CY2021	us-gaap	Depreciation Depreciation	398744	USD
CY2020	us-gaap	Depreciation Depreciation	50655	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	165877	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148541	USD
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	40785	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	40786	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	167202	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10018	USD
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	37500	USD
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	32637	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1647391	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1261215	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44081	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1012	USD
CY2021	sgbx	Gain Loss From Equity Affiliaties GainLossFromEquityAffiliaties	-55	USD
CY2020	sgbx	Gain Loss From Equity Affiliaties GainLossFromEquityAffiliaties		USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	449240	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	890531	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1261220	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1166692	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	495681	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	647345	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61778	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	489437	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-473331	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-81256	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3606889	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1129189	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-337161	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1236174	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-701110	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	965561	USD
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-5000	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	5000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-472492	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-82553	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-662759	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2887950	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4824756	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1568115	USD
CY2021	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses		USD
CY2020	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	743168	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	42500	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	225000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		USD
CY2020	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	650000	USD
CY2021	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	194969	USD
CY2020	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	84440	USD
CY2021	sgbx	Payments For Project Development Costs PaymentsForProjectDevelopmentCosts	630470	USD
CY2020	sgbx	Payments For Project Development Costs PaymentsForProjectDevelopmentCosts		USD
CY2021	sgbx	Payment On Security Deposit PaymentOnSecurityDeposit	203562	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10148041	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17318358	USD
CY2020	sgbx	Payment On Security Deposit PaymentOnSecurityDeposit		USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	200000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		USD
CY2021	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	3600000	USD
CY2020	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture		USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9471257	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3045723	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	10487753	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	17118480	USD
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	707188	USD
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		USD
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2000000	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	51766	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	750000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	200000	USD
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3745134	USD
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		USD
CY2021	sgbx	Settlement Of Common Stock From Reverse Stock Splits SettlementOfCommonStockFromReverseStockSplits		USD
CY2020	sgbx	Settlement Of Common Stock From Reverse Stock Splits SettlementOfCommonStockFromReverseStockSplits	122	USD
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14025	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11384685	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13010356	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1625671	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13024381	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13010356	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	562	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2614	USD
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		USD
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	200000	USD
CY2021	sgbx	Noncashconversionofinterestexpenseoflongtermdebt Noncashconversionofinterestexpenseoflongtermdebt		USD
CY2020	sgbx	Noncashconversionofinterestexpenseoflongtermdebt Noncashconversionofinterestexpenseoflongtermdebt	6263	USD
CY2020Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-<span style="border-left: none; border-right: none;">20</span>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13024381	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3200000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3217909	USD
CY2020Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1522339	USD
CY2020Q2	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	15596141	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: 'times new roman', times; font-size: 10pt;"> <div> <div style="border-left: none; border-right: none;"> <div style="border-left: none; border-right: none;"> <div> <div> <p style="color: #000000; font: 10pt 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.5in;"><span style="color: black;"><b><i>Accounting estimates<span> </span></i></b>– The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period, together with amounts disclosed in the related notes to the financial statements. The Company's estimates used in these financial statements include, but are not limited to, revenue recognition, <span style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">stock-based compensation, accounts receivable reserves, inventory valuations, goodwill, the valuation allowance related to the Company’s deferred tax assets, the carrying amount of intangible assets, right of use assets and the recoverability and useful lives of long-lived assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.</span> </span></p> <p style="color: #000000; font: 10pt 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.5in;"><br/></p> </div> </div> </div> </div> </div> </div>
CY2021	sgbx	Operating Cycle Description OperatingCycleDescription	The length of the Company’s contracts varies, but is typically between <span style="border-left: none; border-right: none;"><span style="border-left: none; border-right: none;"><span style="border-right: none; border-left: none;">six</span></span></span> to <span style="border-left: none; border-right: none;"><span style="border-left: none; border-right: none;"><span style="border-right: none; border-left: none;">twelve</span></span></span> months.
CY2021	sgbx	Warranty Offered On Completed Contracts WarrantyOfferedOnCompletedContracts	P1Y
CY2019Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.50	pure
CY2019Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	2500	shares
CY2020Q3	sgbx	Common Stock Vest And Be Issued Shares CommonStockVestAndBeIssuedShares	1250	shares
CY2021Q3	sgbx	Common Stock Remaining Vest And Be Issued Shares CommonStockRemainingVestAndBeIssuedShares	1250	shares
CY2021	sgbx	Gross Revenue Expected GrossRevenueExpected	16900000	USD
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	31.4	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segments
CY2020	sgbx	Revenue At Point In Time RevenueAtPointInTime	4057086	USD
CY2020	sgbx	Revenue Recognized Over Time RevenueRecognizedOverTime	4698537	USD
CY2021	sgbx	Total Construction Revenue Segment TotalConstructionRevenueSegment	6793690	USD
CY2021Q4	sgbx	Total Construction Revenue Segment Percentage TotalConstructionRevenueSegmentPercentage	0.18	pure
CY2020	sgbx	Total Construction Revenue Segment TotalConstructionRevenueSegment	4514123	USD
CY2021	sgbx	Accumulated Amortization Related To Deferred Costs AccumulatedAmortizationRelatedToDeferredCosts	91765	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40785	USD
CY2020Q4	sgbx	Total Construction Revenue Segment Percentage TotalConstructionRevenueSegmentPercentage	0.51	pure
CY2021	sgbx	Total Medical Revenue Segment TotalMedicalRevenueSegment	31548012	USD
CY2021Q4	sgbx	Total Medical Revenue Segment Percentage TotalMedicalRevenueSegmentPercentage	0.82	pure
CY2020	sgbx	Total Medical Revenue Segment TotalMedicalRevenueSegment	4241500	USD
CY2020Q4	sgbx	Total Medical Revenue Segment Percentage TotalMedicalRevenueSegmentPercentage	0.49	pure
CY2021	sgbx	Revenue From Contract With Segments Customer Excluding Assessed Tax Percentage RevenueFromContractWithSegmentsCustomerExcludingAssessedTaxPercentage	1	pure
CY2020	sgbx	Revenue From Contract With Segments Customer Excluding Assessed Tax RevenueFromContractWithSegmentsCustomerExcludingAssessedTax	8755623	USD
CY2020	sgbx	Revenue From Contract With Segments Customer Excluding Assessed Tax Percentage RevenueFromContractWithSegmentsCustomerExcludingAssessedTaxPercentage	1	pure
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	306143	USD
CY2021Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	102217	USD
CY2021Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	203926	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40786	USD
CY2021	sgbx	License Consideration Description LicenseConsiderationDescription	In consideration for the License, during the initial term, the Licensee agreed to pay the Company a royalty of (x) five percent (5%) on the first $20,000,000 of gross revenues derived from the Licensee’s com mercialization of the License (net of customary discounts, sales taxes, delivery charges, and amounts for returns) (the “Gross Revenues”), (y) four and one-half percent (4.5%) on the next $30,000,000 of Gross Revenues, and (z) five percent (5%) on all Gross Revenues thereafter (collectively, the “Royalty”), subject to the following minimum royalty payments determined on a cumulative basis during the initial term: $500,000 in year 1, $750,000 in year 2, $1,500,000 in year 3, $2,000,000 in year 4, and $2,500,000 in year 5.
CY2021	sgbx	Concentration Risk Percentage ConcentrationRiskPercentage	0.50	pure
CY2021	sgbx	Redemption Distributions RedemptionDistributions	1250000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	200000	shares
CY2021	us-gaap	Other Income OtherIncome	60000	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	965561	USD
CY2020	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	641178	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	420773	USD
CY2021	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	350329	USD
CY2021Q2	us-gaap	Members Equity Attributable To Noncontrolling Interest MembersEquityAttributableToNoncontrollingInterest	10	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13024381	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13010356	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021	us-gaap	Bankruptcy Proceedings Description Of Proceedings BankruptcyProceedingsDescriptionOfProceedings	Intangible assets consist of $2,766,000 of proprietary knowledge and technology, which is being amortized over 20 years. In addition, included in intangible assets is $97,164 of trademarks, and $47,800 of website costs that are being amortized over 5 years.
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	165877	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	649855	USD
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	148541	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	162970	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	161175	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	160469	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	157051	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	139717	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1313850	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2095232	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10018	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin: 0pt 0pt 0pt 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Concentrations of credit risk </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">–</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> Financial instruments, that potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents. The Company places its cash with high credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limits. The Company has not experienced any losses in such account and believes that it is not exposed to any significant credit risk on the account.</span></p> <p style="margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="margin: 0pt 0pt 0pt 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">With respect to receivables, concentrations of credit risk are limited to a few customers in the construction industry. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers other than normal lien rights. At December 31, 2021 and 2020, 78% and 79%, respectively, of the Company’s gross accounts receivable were due from four and three customers.</span></p> <p style="margin: 0pt; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></p> <p style="margin: 0pt 0pt 0pt 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Revenue in excess of<span> </span></span>10<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">% relating to<span> </span></span>one<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> and<span> three</span></span><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span> </span>customers represented approximately<span> 80</span></span><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">% and<span> 61</span></span><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">% of the Company's total revenue for the year ended December 31, 2021 and 2020, respectively. </span></span></p> <p style="margin: 0pt 0pt 0pt 36pt;"><br/></p> <p style="margin: 0pt 0pt 0pt 36pt;"><span style="background-color: #ffffff;"><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-color: #ffffff;">For the year ending December 31, 2021 and 2020, there were no vendors that represented 10% or more of our cost of revenue.</span></span><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> </span><span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The Company believes it has access to alternative suppliers, with limited disruption to the business, should circumstances change with its existing suppliers.</span></p>
CY2021	sgbx	Number Of Customers NumberOfCustomers	4	Customer
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3880762	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3431522	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	963116	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	795914	USD
CY2021	sgbx	Accounts Receivable Net Amount AccountsReceivableNetAmount	2917646	USD
CY2020	sgbx	Accounts Receivable Net Amount AccountsReceivableNetAmount	2635608	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	963116	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	795914	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	167202	USD
CY2021Q4	sgbx	Costs Incurred On Uncompleted Contracts CostsIncurredOnUncompletedContracts	4272425	USD
CY2020Q4	sgbx	Costs Incurred On Uncompleted Contracts CostsIncurredOnUncompletedContracts	4572581	USD
CY2020Q4	sgbx	Provision For Loss On Uncompleted Contracts ProvisionForLossOnUncompletedContracts		USD
CY2021Q4	sgbx	Estimated Income Loss On Uncompleted Contracts EstimatedIncomeLossOnUncompletedContracts	3156377	USD
CY2020Q4	sgbx	Estimated Income Loss On Uncompleted Contracts EstimatedIncomeLossOnUncompletedContracts	-872302	USD
CY2021Q4	sgbx	Contract Receivables Retainage ContractReceivablesRetainage	3354626	USD
CY2020Q4	sgbx	Contract Receivables Retainage ContractReceivablesRetainage	5444883	USD
CY2021Q4	sgbx	Costs In Excess Of Billings To Date CostsInExcessOfBillingsToDate	4750289	USD
CY2020Q4	sgbx	Costs In Excess Of Billings To Date CostsInExcessOfBillingsToDate	5916487	USD
CY2021Q4	sgbx	Contract With Customer Asset Liability ContractWithCustomerAssetLiability	-1395663	USD
CY2020Q4	sgbx	Contract With Customer Asset Liability ContractWithCustomerAssetLiability	-471604	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	41916	USD
CY2021Q4	sgbx	Accrued Project Development Costs AccruedProjectDevelopmentCosts	77700	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1303136	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1437579	USD
CY2021Q4	sgbx	Contract With Customer Asset Liability ContractWithCustomerAssetLiability	-1395663	USD
CY2020Q4	sgbx	Contract With Customer Asset Liability ContractWithCustomerAssetLiability	-471604	USD
CY2021Q4	sgbx	Project Development Costs Non Current ProjectDevelopmentCostsNonCurrent	719610	USD
CY2021Q4	sgbx	Security Deposits Non Current SecurityDepositsNonCurrent	203562	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7249222	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2741514	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	409279	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58500	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6839943	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2683014	USD
CY2020	us-gaap	Depreciation Depreciation	50655	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	37500	USD
CY2020Q4	us-gaap	Interest Income Other InterestIncomeOther	32637	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3784662	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3012338	USD
CY2021Q4	sgbx	Accrued Public Fees AccruedPublicFees	121749	USD
CY2020Q4	sgbx	Accrued Public Fees AccruedPublicFees	79448	USD
CY2021Q4	sgbx	Accrued Construction AccruedConstruction	367298	USD
CY2020Q4	sgbx	Accrued Construction AccruedConstruction	408600	USD
CY2021Q4	sgbx	Accrued Losses AccruedLosses	2238578	USD
CY2020Q4	sgbx	Accrued Losses AccruedLosses		USD
CY2021Q4	sgbx	Accrued Medical AccruedMedical	208512	USD
CY2020Q4	sgbx	Accrued Medical AccruedMedical	180000	USD
CY2021Q4	sgbx	Accrued Generaland Administrative AccruedGeneralandAdministrative	176432	USD
CY2020Q4	sgbx	Accrued Generaland Administrative AccruedGeneralandAdministrative	71014	USD
CY2021Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	545003	USD
CY2020Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	210561	USD
CY2021Q4	sgbx	Accrued Interest AccruedInterest	11333	USD
CY2020Q4	sgbx	Accrued Interest AccruedInterest		USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	37584	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	7568851	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	3961961	USD
CY2020Q4	sgbx	Accrued Project Development Costs AccruedProjectDevelopmentCosts		USD
CY2021Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	USD
CY2021Q3	sgbx	Net Loan Proceed NetLoanProceed	1948234	USD
CY2021Q3	us-gaap	Short Term Debt Terms ShortTermDebtTerms	The Short-Term Note has a term of one (1) year, provides for payments of interest only at a rate of twelve percent (12%) per annum and may be prepaid without penalty commencing nine (9) months after its issuance date.
CY2021Q3	sgbx	Percentage Of Prepayment Penalty PercentageOfPrepaymentPenalty	0.005	pure
CY2021	sgbx	Short Term Debt Interest Charges ShortTermDebtInterestCharges	112348	USD
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	23727	USD
CY2021Q4	sgbx	Value Of Renovation Improvements ValueOfRenovationImprovements	750000	USD
CY2021Q4	sgbx	Principal Amount Of Promissory Note PrincipalAmountOfPromissoryNote	750000	USD
CY2020Q3	sgbx	Acquisition Cash AcquisitionCash	1059600	USD
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1059600	USD
CY2021	sgbx	Business Combination Consideration Transferred Earnout Liability Incurred BusinessCombinationConsiderationTransferredEarnoutLiabilityIncurred		USD
CY2021	sgbx	Business Combination Consideration Transferred Settlement Of Accounts Receivable And Net Contract Liabilities Incurred BusinessCombinationConsiderationTransferredSettlementOfAccountsReceivableAndNetContractLiabilitiesIncurred	-94980	USD
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	964620	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	316432	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	252557	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	130799	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	7400	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	1154818	USD
CY2021Q4	sgbx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Rightofuseassets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseassets	57120	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	85810	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	68344	USD
CY2021Q4	sgbx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses	733529	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	285204	USD
CY2021Q4	sgbx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contractliabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractliabilities	32807	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	57120	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	964620	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2021	us-gaap	Lessor Direct Financing Lease Description LessorDirectFinancingLeaseDescription	The leases have remaining lease terms of one and a half years to four years. The plant lease includes an option to extend the lease for up to five years.
CY2021Q4	sgbx	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	1177879	USD
CY2021Q4	sgbx	Operating Lease Liabilities Current OperatingLeaseLiabilitiesCurrent	317977	USD
CY2021Q4	sgbx	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	860481	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1178458	USD
CY2021Q4	sgbx	Right Of Use Assets Finance Leases RightOfUseAssetsFinanceLeases	32174	USD
CY2021Q4	sgbx	Lease Liability Current Maturities LeaseLiabilityCurrentMaturities	-19492	USD
CY2021Q4	sgbx	Lease Liability Non Current Liabilities LeaseLiabilityNonCurrentLiabilities	-11643	USD
CY2021Q4	sgbx	Total Finance Lease Liabilities TotalFinanceLeaseLiabilities	-31135	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M8D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M9D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.03	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.03	pure
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	348984	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	20160	USD
CY2021Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	369144	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	330300	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	11760	USD
CY2021Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	342060	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	324000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		USD
CY2021Q4	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	324000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	243000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		USD
CY2021Q4	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	243000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		USD
CY2021Q4	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear		USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1246284	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	31920	USD
CY2021Q4	us-gaap	Other Commitment OtherCommitment	1278204	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	67826	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	785	USD
CY2021Q4	sgbx	Total Operating Imputed Interest TotalOperatingImputedInterest	68611	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1178458	USD
CY2021Q4	sgbx	Financing Lease Liability FinancingLeaseLiability	31135	USD
CY2021Q4	sgbx	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	1209593	USD
CY2020Q4	sgbx	Construction Contracts Backlog ConstructionContractsBacklog	25117461	USD
CY2019Q4	sgbx	Construction Contracts Backlog ConstructionContractsBacklog	17634261	USD
CY2021	sgbx	New Contracts Received During Year NewContractsReceivedDuringYear	3191335	USD
CY2020	sgbx	New Contracts Received During Year NewContractsReceivedDuringYear	13816785	USD
CY2021	sgbx	Adjustments And Cancellations Net AdjustmentsAndCancellationsNet	-18297197	USD
CY2020	sgbx	Adjustments And Cancellations Net AdjustmentsAndCancellationsNet	-27370	USD
CY2021	sgbx	Construction Backlog Gross ConstructionBacklogGross	10011599	USD
CY2020	sgbx	Construction Backlog Gross ConstructionBacklogGross	31423676	USD
CY2021	sgbx	Contract Revenue ContractRevenue	-6793690	USD
CY2020	sgbx	Contract Revenue ContractRevenue	-6306215	USD
CY2021Q4	sgbx	Construction Contracts Backlog ConstructionContractsBacklog	3217909	USD
CY2020Q4	sgbx	Construction Contracts Backlog ConstructionContractsBacklog	25117461	USD
CY2021	sgbx	Contract Backlog Description ContractBacklogDescription	<span style="border-right: none; border-left: none;">two</span> contracts entered into during the third quarter of 2020 in the amount of approximately $4 million and approximately $2.95 million
CY2021Q1	sgbx	Construction Backlog Contract Revenue ConstructionBacklogContractRevenue	1300000	USD
	sgbx	Construction Backlog Contract Revenue ConstructionBacklogContractRevenue	870000	USD
	sgbx	Cancellation Of Construction Backlog Contract Amountbacklogcontract CancellationOfConstructionBacklogContractAmountbacklogcontract	1300000	USD
CY2021	sgbx	Construction Backlog Contract Revenue ConstructionBacklogContractRevenue	780000	USD
CY2021	sgbx	Cancellation Of Construction Backlog Contract Amountbacklogcontract CancellationOfConstructionBacklogContractAmountbacklogcontract	16900000	USD
CY2021	sgbx	Redemption Distributions Amount RedemptionDistributionsAmount	1250000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3217909	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-974181	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-567767	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1541948	USD
CY2021	sgbx	Provision Income Tax Expense Benefit ProvisionIncomeTaxExpenseBenefit		USD
CY2020	sgbx	Provision Income Tax Expense Benefit ProvisionIncomeTaxExpenseBenefit	-1541948	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039	pure
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4127323	USD
CY2021	sgbx	Amount Of Valuation Reserve AmountOfValuationReserve		USD
CY2020	sgbx	Amount Of Valuation Reserve AmountOfValuationReserve	-1541948	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses		pure
CY2021	sgbx	Differences Attributable To Change In State Business Apportionment DifferencesAttributableToChangeInStateBusinessApportionment		pure
CY2020	sgbx	Differences Attributable To Change In State Business Apportionment DifferencesAttributableToChangeInStateBusinessApportionment		pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.249	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts		USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	197785	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits		USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	800036	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-529260	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-44979	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	47184	USD
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards		USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	205	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4598294	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4598294	USD
CY2019Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-08-29
CY2020Q2	sgbx	Warrants To Purchase WarrantsToPurchase	300000	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2020Q2	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	15596141	USD
CY2020Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1653859	USD
CY2020Q2	sgbx	Common Stock Number Of Shares Underwritter CommonStockNumberOfSharesUnderwritter	300000	shares
CY2021Q4	sgbx	Gross Proceeds GrossProceeds	11550000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1541948	USD
CY2020Q4	sgbx	Future Taxable Income Temporarily Removes Percentage FutureTaxableIncomeTemporarilyRemovesPercentage	0.80	pure
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	100
CY2017Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	176771	USD
CY2017Q3	sgbx	Warrants To Purchase Of Common Stock WarrantsToPurchaseOfCommonStock	563	shares
CY2017Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	8321	shares
CY2019Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2117948	USD
CY2020Q2	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1522339	USD
CY2020Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	347661	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6000000	shares
CY2020Q2	sgbx	Options Granted To Purchase Common Stock OptionsGrantedToPurchaseCommonStock	900000	shares
CY2020Q2	sgbx	Common Stock Exercise Price Per Share CommonStockExercisePricePerShare	0.01
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	900000	shares
CY2021Q4	sgbx	Purchaseof Agreement PurchaseofAgreement	Pursuant to the terms of the Purchase Agreement, the Company issued to the investor (A) in a registered direct offering (i) 975,000 shares (the “Public Shares”) of its Common Stock, par value $0.01 per share (the “Common Stock”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,189,384 shares (the “Pre-Funded Warrant Shares”) of Common Stock and (B) in a concurrent private placement, Series A warrants to purchase up to 1,898,630 shares (the “Common Stock Warrant Shares”) of Common Stock (the “Common Stock Warrants,” and together with the Public Shares and the Pre-Funded Warrants, the “Securities”) (the “Offering The Pre-Funded Warrants were immediately exercisable at a nominal exercise price of $0.001 and all Pre-Funded Warrants sold have been exercised. The Common Stock Warrants have an exercise price of $4.80 per share, are exercisable upon issuance and will expire five years from the date of issuance. A.G.P./Alliance Global Partners (the “Placement Agent”) acted as the exclusive placement agent for the transaction pursuant to that certain Placement Agency Agreement, dated as of October 25, 2021, by and between the Company and the Placement Agent (the “Placement Agency Agreement”), the Placement Agent received (i) a cash fee equal to seven percent (7.0%) of the gross proceeds from the placement of the Securities sold by the Placement Agent in the Offering and (ii) a non-accountable expense allowance of one half of one percent (0.5%) of the gross proceeds from the placement of theGross Proceeds Securities sold by the Placement Agent in the Offering. The Company also reimbursed the Placement Agent’s expenses up to $50,000 upon closing the Offering.
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	10500000	USD
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	45000	shares
CY2019Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	17
CY2017Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-06-21
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-10-29
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3625000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1343377	shares
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	81.2
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2020Q2	us-gaap	Share Price SharePrice	3.14
CY2020Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-05-05
CY2021Q4	sgbx	Warrants To Purchase WarrantsToPurchase	1898630	shares
CY2021Q4	us-gaap	Share Price SharePrice	4.8
CY2016Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	25000	shares
CY2021	sgbx	Stock Based Compensation Expens Total Stock-basedCompensationExpensTotal	1647391	USD
CY2020	sgbx	Stock Based Compensation Expens Total Stock-basedCompensationExpensTotal	1261215	USD
CY2021	sgbx	Stock Based Compensation Expens Total Stock-basedCompensationExpensTotal	1647391	USD
CY2020	sgbx	Stock Based Compensation Expens Total Stock-basedCompensationExpensTotal	1261215	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	53170	shares
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	24.8
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2020	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
CY2020	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageFairValue
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16734	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	36436	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	35.54
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	78.71
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M2D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
CY2021	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	36436	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	78.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M2D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2666	USD
CY2020	sgbx	Allocated Share Based Compensation Expense Accrued AllocatedShareBasedCompensationExpenseAccrued	10667	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.88
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	24.8
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	78.71
CY2021	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y4M2D
CY2021Q4	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueOne		USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	36332	shares
CY2020Q4	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue	24.8
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	78.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M2D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	36436	shares
CY2021Q4	sgbx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue	24.8
CY2019Q2	sgbx	Number Of Employees NumberOfEmployees	6	Employee
CY2019Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	3063	shares
CY2019Q1	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	847957	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	9189	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	16.4
CY2020Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	8000	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	12000	shares
CY2020Q2	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	168176	USD
CY2020Q3	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	769250	USD
CY2020Q4	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	111920	USD
CY2020Q4	us-gaap	Share Price SharePrice	3.28
CY2020Q4	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	1220160	USD
CY2021Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1214500	shares
CY2021Q4	us-gaap	Share Price SharePrice	3.38
CY2021Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	475000	shares
CY2019Q2	sgbx	Unpaid Wages UnpaidWages	30428.71	USD
CY2021Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	67125.83	USD
CY2020Q1	sgbx	Unpaid Wages UnpaidWages	372638	USD
CY2020Q1	sgbx	Severance Amount SeveranceAmount	300000	USD
CY2020Q2	sgbx	Unpaid Wages UnpaidWages	300000	USD
CY2021Q4	sgbx	Fair Value Of Restricted Units FairValueOfRestrictedUnits	4105010	USD
CY2021Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	62500	shares
CY2021Q4	us-gaap	Share Price SharePrice	2.36
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3955323	USD
CY2019Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	2100000	USD
CY2018Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	761401.66	USD
CY2020Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	2861401.66	USD
CY2020Q2	us-gaap	Other Commitments Description OtherCommitmentsDescription	provide for an annual base salary of $400,000, provide for a performance bonus structure for a bonus of up to 50% of base salary upon the Company’s achievement of $2,000,000 EBITDA and additional performance bonus payments for the achievement of EBITDA in excess of $2,000,000 based on a percentage of the incremental increase in EBITDA (ranging from 10% of the incremental increase in EBITDA if the Company achieves over $2,000,000 and up to $7,000,000 in EBITDA, 8% of the incremental increase in EBITDA if the Company achieves over $7,000,000 and up to $12,000,000 in EBITDA and 3% of the incremental increase in EBITDA over $12,000,000), provide for a profits-based additional bonus of up to $250,000 in certain limited circumstances, and provide for one (1) year severance, plus a pro-rated amount of any unpaid bonus earned by him during the year as verified by the Company’s principal financial officer, if Mr. Galvin is terminated without cause. At the Company’s option, up to fifty (50%) percent of the EBITDA performance bonuses may be paid in restricted stock units if then available for grant under the Company’s Stock Incentive Plan. All other terms of the employment agreement remain in full force and effect.
CY2021Q4	us-gaap	Area Of Land AreaOfLand	114	acre
CY2021Q4	us-gaap	Residual Value Of Leased Asset ResidualValueOfLeasedAsset	870000	USD
CY2021Q4	sgbx	Number Of Residential Units NumberOfResidentialUnits	300	ResidentialUnits
CY2021Q4	us-gaap	Net Rentable Area NetRentableArea	680000
CY2021	sgbx	Principal Amount Of Promissory Note PrincipalAmountOfPromissoryNote	100000	USD
CY2020Q1	sgbx	Originalpromissorynoteissued Originalpromissorynoteissued	100000	USD

Files In Submission

Name	View Source	Status
0001213900-22-020226-index-headers.html	Edgar Link	pending
0001213900-22-020226-index.html	Edgar Link	pending
0001213900-22-020226.txt	Edgar Link	pending
0001213900-22-020226-xbrl.zip	Edgar Link	pending
ex211_2.htm	Edgar Link	pending
ex231_3.htm	Edgar Link	pending
ex311_4.htm	Edgar Link	pending
ex312_5.htm	Edgar Link	pending
ex321_6.htm	Edgar Link	pending
ex48_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgbx-20211231.htm	Edgar Link	pending
sgbx-20211231.xsd	Edgar Link	pending
sgbx-20211231_cal.xml	Edgar Link	unprocessable
sgbx-20211231_def.xml	Edgar Link	unprocessable
sgbx-20211231_htm.xml	Edgar Link	completed
sgbx-20211231_lab.xml	Edgar Link	unprocessable
sgbx-20211231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGBX
SAFE & GREEN HOLDINGS CORP. Stock $sgbx

2021 Q4 Form 10-K Financial Statement

#000121390022020226 Filed on April 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGBX SAFE & GREEN HOLDINGS CORP. Stock $sgbx

2021 Q4 Form 10-K Financial Statement

#000121390022020226 Filed on April 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGBX
SAFE & GREEN HOLDINGS CORP. Stock $sgbx